Peptide Research: Hexarelin – Studies, Research Use, and Scientific Background

What is Hexarelin?

Hexarelin is a synthetic hexapeptide growth hormone secretagogue and potent agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a). In laboratory research, Hexarelin is studied for its effects on growth hormone release, cardiovascular health, and metabolic function in preclinical models.
For laboratory research use only. Not for human or veterinary use.

Key Scientific Studies

• Growth Hormone Stimulation: A study published in Journal of Clinical Endocrinology & Metabolism (1997) demonstrated that Hexarelin strongly stimulates growth hormone release in both animal models and healthy human volunteers.
  Bowers et al., 1997
• Cardioprotective Effects: Laboratory research has indicated that Hexarelin may protect cardiac tissue and improve cardiac function after experimentally induced heart injury in animal models.
  Lodola et al., 2002

Laboratory Research Applications

• Investigation of growth hormone regulation and secretion
• Preclinical models of metabolic and endocrine disorders
• Research on cardiac protection and recovery
• Studies of ghrelin receptor activation mechanisms

Mechanism of Action (in Research Context)

Hexarelin binds to the growth hormone secretagogue receptor (GHS-R1a), stimulating robust growth hormone release from the pituitary gland. In laboratory studies, it has also shown cardioprotective effects, possibly through anti-apoptotic and anti-fibrotic pathways in cardiac tissue.

Reference Dosing Schedules from Published Studies

The following dosing protocols have been reported in published laboratory and preclinical studies of Hexarelin:

• Common Dose Range (animal studies): 50–100 mcg/kg, administered subcutaneously or intravenously
• Duration: Varies by protocol; typically 7–21 days in preclinical models